Published: January 2012
Solitary Fibrous Tumor of the Prostate: Case Report and Review of the LiteratureMoureau-Zabotto L.a · Chetaille B.b · Bladou F.h · Dauvergne P.-Y.g · Marcy M.b · Perrot D.e · Guiramand J.c · Sarran A.d · Bertucci F.e, f
Departments of aRadiotherapy, bPathology, cSurgical Oncology, dRadiology, and eMedical Oncology, Institut Paoli-Calmettes, and fUniversity of Mediterranea, Marseille, gClinique Rhône-Durance, Avignon, France; hDepartment of Urology, Jewish General Hospital, Montreal, Que., Canada
Prof. François Bertucci
Department of Medical Oncology, Institut Paoli-Calmettes
232, bd Ste-Marguerite
FR–13273 Marseille Cedex 09 (France)
Tel. +33 4 91 22 35 37, E-Mail email@example.com
Do you have an account?
Solitary fibrous tumor (SFT), usually described in the pleura, is exceedingly rare in the prostate. We report a 60-year-old man with prostatic SFT revealed by obstructive urinary symptoms, and detected by ultrasonography. Computed tomography (CT) and magnetic resonance imaging suggested a prostatic origin. CT-guided tumor biopsy diagnosed a SFT. A cystoprostatectomy was performed. Pathologic examination showed a 15-cm tumor arising from the prostate and showing histological criteria suggestive of aggressiveness. The surgical resection margins were tumor-free. The patient was then regularly monitored and is still alive in complete remission, 28 months after surgery. In conclusion, we report a new exceptional case of prostatic SFT. We review the literature and discuss the challenging issues of misdiagnosis, prognosis and treatment.
© 2012 S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / DisclaimerOpen Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.